I did a whole article on FDA CBER Director Dr Peter Marks’ talk where he focused exclusively on the potential for gene therapy and the FDA’s commitment to it. There is optimism and positive ...

Ablynx is looking for new partners to take its rheumatoid arthritis drug vobarilizumab into phase 3 development, after AbbVie turned down an option to license the drug. AbbVie has already paid the ...

A multibillion-dollar partnership between AbbVie and Genmab risks being soured by a lawsuit claiming misappropriation of trade secrets. Specifically, it focuses on the use of disaccharides to ...

As the race to deliver personalised engagement at scale heats up, artificial intelligence (AI) has become the critical differentiator for pharma companies, turning vast data streams into ...

The pharmaceutical construction industry has seen explosive growth, a trend with substantial implications for healthcare industry, and global health outcomes. The COVID-19 pandemic underscored the ...

It is slightly ahead of Bellus Health with BLU-5937, another P2X3 inhibitor, which hit the mark in the mid-stage SOOTHE trial a few weeks later after disappointing in an earlier readout.

Novartis is one of the world's top pharmaceutical companies, and along with neighbours Roche, the mainstay of Switzerland's centuries-long contribution to new medicines. Headquartered in Basel ...

The litany of big-ticket deals involving antibody-drug conjugates shows no sign of ending. In the latest recitation, Bristol-Myers Squibb is paying $800 million upfront for rights to a HER3-direct ...

Effective KOL management is more than just tracking which activities your KOLs have engaged with. It’s also about tracking the effectiveness of those activities, and the resulting impact on KOL ...

Vinay Prasad will replace Marks as CBER director Trump's budget would be "catastrophic" for federal R&D Pharma still in waiting mode after UK-US trade agreement ...

Vinay Prasad will replace Marks as CBER director Trump's budget would be "catastrophic" for federal R&D Pharma still in waiting mode after UK-US trade agreement ...

Jean-François Toussaint, Sanofi's global head of vaccines R&D, speaking at a conference at the company's site in Lyon last year. There are currently no approved vaccines to protect against ...